Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1/IL-2α-bias Bispecific Antibody Fusion Protein in Advanced ESCC
NCT07688291Phase 2Not yet recruiting
- Sponsor
- Beijing Gaobo Hospital
- Start
- Jun 2026
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
A Phase 2 trial of IBI363 in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Beijing Gaobo Hospital. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
IBI363
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07688291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07688291.